You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2024

Details for Patent: 8,287,847


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,287,847 protect, and when does it expire?

Patent 8,287,847 protects VELTASSA and is included in one NDA.

This patent has ninety-six patent family members in seventeen countries.

Summary for Patent: 8,287,847
Title:Ion binding polymers and uses thereof
Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.
Inventor(s): Charmot; Dominique (Campbell, CA), Chang; Han-Ting (Livermore, CA), Liu; Mingjun (Campbell, CA), Klaerner; Gerrit (San Jose, CA)
Assignee: Relypsa, Inc. (Santa Clara, CA)
Application Number:12/055,765
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,287,847
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 8,287,847

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Vifor Pharma VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-004 Oct 2, 2023 RX Yes No ⤷  Sign Up ⤷  Sign Up TREATMENT OF HYPERKALEMIA ⤷  Sign Up
Vifor Pharma VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-001 Oct 21, 2015 RX Yes No ⤷  Sign Up ⤷  Sign Up TREATMENT OF HYPERKALEMIA ⤷  Sign Up
Vifor Pharma VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-002 Oct 21, 2015 RX Yes Yes ⤷  Sign Up ⤷  Sign Up TREATMENT OF HYPERKALEMIA ⤷  Sign Up
Vifor Pharma VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-003 Oct 21, 2015 DISCN Yes No ⤷  Sign Up ⤷  Sign Up TREATMENT OF HYPERKALEMIA ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,287,847

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1732523 ⤷  Sign Up 300924 Netherlands ⤷  Sign Up
European Patent Office 2269589 ⤷  Sign Up CA 2018 00003 Denmark ⤷  Sign Up
European Patent Office 1732523 ⤷  Sign Up 300925 Netherlands ⤷  Sign Up
European Patent Office 1732523 ⤷  Sign Up 122018000011 Germany ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.